Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

Based on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy o...

Full description

Bibliographic Details
Main Authors: Jiahui Yang, Sivasubramanian Baskar, Ka Yin Kwong, Michael G Kennedy, Adrian Wiestner, Christoph Rader
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3115963?pdf=render
id doaj-6f239d23702e46eeb452a110423a5022
record_format Article
spelling doaj-6f239d23702e46eeb452a110423a50222020-11-25T01:28:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0166e2101810.1371/journal.pone.0021018Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.Jiahui YangSivasubramanian BaskarKa Yin KwongMichael G KennedyAdrian WiestnerChristoph RaderBased on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated.A chimeric rabbit/human Fab library was generated from immunized rabbits and selected by phage display. Chimeric rabbit/human Fab and IgG1 were investigated for their capability to bind to human and mouse ROR1, to mediate antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and internalization, and to agonize or antagonize apoptosis using primary CLL cells from untreated patients as well as MCL cell lines. A panel of mAbs demonstrated high affinity and specificity for a diverse set of epitopes that involve all three extracellular domains of ROR1, are accessible on the cell surface, and mediate internalization. The mAb with the highest affinity and slowest rate of internalization was found to be the only mAb that mediated significant, albeit weak, ADCC. None of the mAbs mediated CDC. Alone, they did not enhance or inhibit apoptosis.Owing to its relatively low cell surface density, ROR1 may be a preferred target for armed rather than naked mAbs. Provided is a panel of fully sequenced and thoroughly characterized anti-ROR1 mAbs suitable for conversion to antibody-drug conjugates, immunotoxins, chimeric antigen receptors, and other armed mAb entities for preclinical and clinical studies.http://europepmc.org/articles/PMC3115963?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jiahui Yang
Sivasubramanian Baskar
Ka Yin Kwong
Michael G Kennedy
Adrian Wiestner
Christoph Rader
spellingShingle Jiahui Yang
Sivasubramanian Baskar
Ka Yin Kwong
Michael G Kennedy
Adrian Wiestner
Christoph Rader
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
PLoS ONE
author_facet Jiahui Yang
Sivasubramanian Baskar
Ka Yin Kwong
Michael G Kennedy
Adrian Wiestner
Christoph Rader
author_sort Jiahui Yang
title Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
title_short Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
title_full Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
title_fullStr Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
title_full_unstemmed Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
title_sort therapeutic potential and challenges of targeting receptor tyrosine kinase ror1 with monoclonal antibodies in b-cell malignancies.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Based on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated.A chimeric rabbit/human Fab library was generated from immunized rabbits and selected by phage display. Chimeric rabbit/human Fab and IgG1 were investigated for their capability to bind to human and mouse ROR1, to mediate antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and internalization, and to agonize or antagonize apoptosis using primary CLL cells from untreated patients as well as MCL cell lines. A panel of mAbs demonstrated high affinity and specificity for a diverse set of epitopes that involve all three extracellular domains of ROR1, are accessible on the cell surface, and mediate internalization. The mAb with the highest affinity and slowest rate of internalization was found to be the only mAb that mediated significant, albeit weak, ADCC. None of the mAbs mediated CDC. Alone, they did not enhance or inhibit apoptosis.Owing to its relatively low cell surface density, ROR1 may be a preferred target for armed rather than naked mAbs. Provided is a panel of fully sequenced and thoroughly characterized anti-ROR1 mAbs suitable for conversion to antibody-drug conjugates, immunotoxins, chimeric antigen receptors, and other armed mAb entities for preclinical and clinical studies.
url http://europepmc.org/articles/PMC3115963?pdf=render
work_keys_str_mv AT jiahuiyang therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies
AT sivasubramanianbaskar therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies
AT kayinkwong therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies
AT michaelgkennedy therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies
AT adrianwiestner therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies
AT christophrader therapeuticpotentialandchallengesoftargetingreceptortyrosinekinaseror1withmonoclonalantibodiesinbcellmalignancies
_version_ 1725100306400804864